An evolutionary approach to optimizing glucose‐6‐phosphatase‐α enzymatic activity for gene therapy of glycogen storage disease type Ia
- 3 February 2019
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (3) , 470-479
Abstract
Glycogen storage disease type‐Ia (GSD‐Ia), caused by a deficiency in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC), is characterized by impaired glucose homeostasis with a hallmark hypoglycemia, following a short fast. We have shown that G6pc‐deficient (G6pc−/−) mice treated with recombinant adeno‐associated virus (rAAV) vectors expressing either wild‐type (WT) (rAAV‐hG6PC‐WT) or codon‐optimized (co) (rAAV‐co‐hG6PC) human (h) G6Pase‐α maintain glucose homeostasis if they restore ≥3% of normal hepatic G6Pase‐α activity. The co vector, which has a higher potency, is currently being used in a phase I/II clinical trial for human GSD‐Ia (NCT 03517085). While routinely used in clinical therapies, co vectors may not always be optimal. Codon‐optimization can impact RNA secondary structure, change RNA/DNA protein‐binding sites, affect protein conformation and function, and alter posttranscriptional modifications that may reduce potency or efficacy. We therefore sought to develop alternative approaches to increase the potency of the G6PC gene transfer vectors. Using an evolutionary sequence analysis, we identified a Ser‐298 to Cys‐298 substitution naturally found in canine, mouse, rat, and several primate G6Pase‐α isozymes, that when incorporated into the WT hG6Pase‐α sequence, markedly enhanced enzymatic activity. Using G6pc−/− mice, we show that the efficacy of the rAAV‐hG6PC‐S298C vector was 3‐fold higher than that of the rAAV‐hG6PC‐WT vector. The rAAV‐hG6PC‐S298C vector with increased efficacy, that minimizes the potential problems associated with codon‐optimization, offers a valuable vector for clinical translation in human GSD‐Ia.Keywords
Funding Information
- National Institute of Child Health and Human Development (HD000912-38)
This publication has 24 references indexed in Scilit:
- Long-Term Efficacy Following Readministration of an Adeno-Associated Virus Vector in Dogs with Glycogen Storage Disease Type IaHuman Gene Therapy, 2012
- Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapyHepatology, 2012
- Recombinant AAV-directed gene therapy for type I glycogen storage diseasesExpert Opinion on Biological Therapy, 2011
- Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapyNature Reviews Endocrinology, 2010
- Adeno-Associated Virus-Mediated Correction of a Canine Model of Glycogen Storage Disease Type IaHuman Gene Therapy, 2010
- Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage Disease Type Ia Using Gene TherapyMolecular Therapy, 2010
- Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I)European Journal of Pediatrics, 2002
- The Molecular Basis of Glycogen Storage Disease Type 1aJournal of Biological Chemistry, 2002
- Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I)European Journal of Pediatrics, 2002
- Glucose–6–phosphatase dependent substrate transport in the glycogen storage disease type–1a mouseNature Genetics, 1996